Chagnon Yvon C
Laval University Robert-Giffard Research Center, Beauport, Québec, Canada.
Curr Drug Targets. 2006 Dec;7(12):1681-95. doi: 10.2174/138945006779025400.
Antipsychotic-induced body weight gain is becoming a major health concern since the increasing use of this medication in different mental disorders with a high prevalence in different populations. The percentage of patients gaining weight following antipsychotic medication can reach up to 80% according to the antipsychotic used, with around 30% developing obesity. The origins of this adverse effect of antipsychotics are probably multifactorial with the environment (food and exercise habits, medication) and the genetics coming into play. We have compiled the available genetic results on the antipsychotic-induced body weight gain and obesity. Candidate genes analysis showed that six genes have been associated with this adverse effect of antipsychotics. Among these, the associations with the serotonin receptor 2C and the leptin genes have been observed in more then one study. Thirteen other genes, mainly antipsychotic known receptors, have shown negative results. To find informative gene variations, we have also compared the effects of some polymorphisms of the serotonin receptor 2C and 2A in mental disorders, for antipsychotic therapeutic effect, for antipsychotic neuronal side effects, and for obesity. We have found results for six polymorphisms in each of the two genes. When association was observed for more then one phenotype, the same genotype or allele was generally involved identifying those sensitive to environmental pressures and to genetic background. Animal transgenic models of knockout or overexpressed genes of antipsychotic receptors have been evaluated for changes in obesity-related phenotypes. Seventeen out of the twenty-three antipsychotic receptors with transgenic models showed some effects on obesity-related phenotypes. Ten of these receptors have not been tested yet for antipsychotic-induced body weight gain, while the others have been tested only once with negative results, or is already associated to the effect such as the serotonin receptor 2C. Finally, pharmacogenomic approaches have allowed to detect more then 300 possible candidate genes for antipsychotic-induced body weight gain.
随着抗精神病药物在不同精神障碍中的使用日益增加,且在不同人群中患病率较高,抗精神病药物引起的体重增加正成为一个主要的健康问题。根据所使用的抗精神病药物不同,用药后体重增加的患者比例可达80%,约30%的患者会发展为肥胖。抗精神病药物这种不良反应的起源可能是多因素的,环境(饮食和运动习惯、药物)和基因都发挥了作用。我们汇总了关于抗精神病药物引起体重增加和肥胖的现有基因研究结果。候选基因分析表明,有六个基因与抗精神病药物的这种不良反应有关。其中,血清素受体2C和瘦素基因的关联在不止一项研究中被观察到。其他十三个基因,主要是已知的抗精神病药物受体,结果为阴性。为了找到有信息价值的基因变异,我们还比较了血清素受体2C和2A的一些多态性在精神障碍、抗精神病治疗效果、抗精神病药物的神经副作用以及肥胖方面的影响。我们在这两个基因中各发现了六个多态性的相关结果。当观察到与不止一种表型有关联时,通常涉及相同的基因型或等位基因,从而确定那些对环境压力和遗传背景敏感的个体。已经评估了抗精神病药物受体基因敲除或过表达的动物转基因模型在肥胖相关表型方面的变化。二十三个有转基因模型的抗精神病药物受体中,有十七个对肥胖相关表型有一些影响。其中十个受体尚未针对抗精神病药物引起的体重增加进行测试,而其他受体仅测试过一次,结果为阴性,或者已经与该效应相关,如血清素受体2C。最后,药物基因组学方法已能够检测出300多个可能与抗精神病药物引起体重增加相关的候选基因。